Combined drug therapy for ovarian carcinoma.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D002455:Cell Division / Q000187:drug effects; D003036:Cobalt Isotopes; D003561:Cytarabine / Q000627:therapeutic use; D004273:DNA, Neoplasm; D004357:Drug Synergism; D005260:Female; D006801:Humans; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D011241:Prednisone / Q000627:therapeutic use; D011867:Radioisotope Teletherapy
D000970:Antineoplastic Agents; D003036:Cobalt Isotopes; D004273:DNA, Neoplasm; D003561:Cytarabine; D011241:Prednisone